Annonce • Aug 20
XOMA Royalty Corporation (NasdaqGM:XOMA) entered into a definitive agreement to acquire Mural Oncology plc (NasdaqGM:MURA) for $35.3 million. XOMA Royalty Corporation (NasdaqGM:XOMA) proposed to acquire Mural Oncology plc (NasdaqGM:MURA) on June 9, 2025. XOMA Royalty Corporation entered into a definitive agreement to acquire Mural Oncology plc for $35.3 million on August 20, 2025. A cash consideration valued at $2.035 per share will be paid by XOMA Royalty Corporation for 17.324771 million shares. XOMA Royalty Corporation will pay an earnout/contingent payment of $3.56 million cash. Pursuant to the terms of the Transaction Agreement and subject to certain conditions and the closing of the Acquisition shareholders (i) are entitled to receive a base cash price of $2.035 per share, which has been calculated on the basis of the Company having approximately $36.2 million of closing net cash and is payable to the Company’s shareholders at the Closing regardless of the actual amount of the Company’s closing net cash on or before the Closing, and (ii) may receive an additional cash amount per share of up to $0.205. The Consideration payable under the terms of the Acquisition will be funded by XOMA Royalty’s existing cash and cash equivalent resources.
The transaction is subject to approval of offer by target shareholders, subject to antitrust regulations, all required Clearances of any Governmental Entity and subject to court approval. The transaction has been approved by board of Mural Oncology and XOMA Royalty. The transaction is expected to close in fourth quarter of 2025.
Lucid Capital Markets, LLC acted as financial advisor for Mural Oncology plc. Gibson, Dunn & Crutcher LLP acted as legal advisor for XOMA Royalty Corporation. Mason Hayes & Curran Solicitors acted as legal advisor for XOMA Royalty Corporation. Christopher McLaughlin and David Vos of Arthur Cox LLP acted as legal advisor for Mural Oncology plc. Stuart M. Falber, Mark Nylen and Scott Lunin of Wilmer Cutler Pickering Hale and Dorr LLP acted as legal advisor for Mural Oncology plc. Annonce • Apr 29
Mural Oncology plc, Annual General Meeting, Jun 11, 2025 Mural Oncology plc, Annual General Meeting, Jun 11, 2025. Location: arthur coxllpat ten earlsfort terrace, d02 t380, ireland, dublin 2 United States Annonce • Apr 16
Mural Oncology plc Announces Reduction in Workforce On April 14, 2025, the board of directors of Mural Oncology plc determined to discontinue all clinical development of nemvaleukin alfa and, in connection with such decision, approved a reduction in the Company’s workforce by approximately 104 positions, or approximately 90%. The Company expects to substantially complete the Reduction by the end of the second quarter of 2025. The Company expects to incur costs of approximately $9.0 million to $10.0 million related to the Reduction, primarily consisting of severance payments and employee benefit costs. Additionally, the Company expects to incur $2.0 million to $4.0 million in non-cash impairment charges associated with property and equipment expected to be sold or otherwise disposed of. The Company may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the Reduction. The costs related to the Reduction are expected to be substantially incurred in the second quarter of 2025. The estimated costs that the Company expects to incur and the estimated timing to complete the Reduction and for the incurrence of the costs are subject to a number of assumptions, and actual results may differ materially from these estimates. Annonce • Apr 15
Mural Oncology plc Announces Plans to Explore Strategic Alternatives Mural Oncology plc announced that following review of data from its phase 2 ARTISTRY-6 trial in melanoma and previously announced results from the phase 3 ARTISTRY-7 trial in platinum-resistant ovarian cancer, the company is discontinuing all clinical development of nemvaleukin alfa and plans to immediately commence the exploration of strategic alternatives focused on maximizing shareholder value. Mural has engaged Lucid Capital Markets, LLC to act as its financial advisor in connection with the exploration of strategic alternatives. The company had approximately $144.4 million of cash, cash equivalents, and marketable securities as of December 31, 2024. In conjunction with today's announcement, Mural plans to reduce its workforce by approximately 90%. ARTISTRY-6, cohort 2 is a phase 2, single-arm trial evaluating nemvaleukin as a monotherapy in 92 patients with mucosal melanoma with a minimum follow-up of at least six months. A review of the topline data from this cohort showed that the primary endpoint was not achieved. Mural also conducted a review of preliminary data from ARTISTRY-6, cohorts 3, evaluating less-frequent intravenous dosing of nemvaleukin in patients with cutaneous melanoma, and did not observe a level of activity that warranted continuation. Based on the totality of these data, together with the interim overall survival results from ARTISTRY-7 as announced on March 25, 2025, Mural will discontinue all clinical development of nemvaleUKin. Mural plans to explore potential strategic alternatives including, but not limited to, an offer for or other acquisition of the company, merger, business combination, or other transaction. While the company has not set a timeline for completion of this process, further updates and developments will be disclosed as appropriate or where necessary under regulatory requirements. There can be no assurance that the exploration of strategic alternatives will result in the company pursuing a transaction or that any acquisition or other transaction involving the company will be completed, nor as to the terms on which any acquisition or other transaction will occur, if at all. The company confirms that, as at the date of this announcement, it is not in receipt of any approaches and not in active discussions with any potential offeror. Mural is subject to the Irish Takeover Panel Act, 1997, Irish Takeover Rules 2022 (the " Irish Takeover Rules"), which have certain implications on some of the strategic alternatives to be explored by the company. As the exploration of strategic alternatives is expected to include consideration of potential offers for the company, following the publication of this announcement Mural is now considered to be in an " offer period" as defined in the Irish Takeover Rules and the dealing disclosure requirements of Rule 8 of the Irish Takeover Rules as summarized below will apply. The Irish Takeover Panel has granted a dispensation from the requirements of Rules 2.4(b) and 2.4(c) of the Irish Takeover Rules such that any potential offeror will not be required to be publicly identified as a result of this announcement for so long as the strategic evaluation is ongoing. Such parties should nonetheless be mind of their obligations under the Irish Takeover Rules, including in particular with respect to confidentiality under Rule 2.1 and the circumstances in which an announcement may be required under Rule 2.2. If a potential offeror has any doubt about its obligations pursuant to the Irish Takeover Rules, it should contact its financial adviser(s) and, where applicable, it should also consult with the Irish Takeover Panel. This is an announcement under Rule 2.4 of the Irish Takeover Rules and is not an announcement of a firm intention by any party to make an offer under Rule 2.7 of the Irish Takeover Rules. Annonce • Mar 25
Mural Oncology plc Provides Update on Phase 3 ARTISTRY-7 Trial of Nemvaleukin in Combination with Keytruda®? (Pembrolizumab) in Patients with Platinum-Resistant Ovarian Cancer Mural Oncology plc announced that the ARTISTRY-7 phase 3 trial of nemvaleukin alfa in combination with Merck's (known as MSD outside the US and Canada) anti-PD-1 therapy, KEYTRUDA®? (pembrolizumab) versus investigator's choice chemotherapy in patients with platinum-resistant ovarian cancer (PROC) will not continue to final analysis and the company will cease development of nemvaleukin for PROC. In the pre-specified interim analysis conducted by the independent data monitoring committee, nemvaleukin in combination with pembrolizumab did not achieve a statistically significant improvement in overall survival versus investigator's choice chemotherapy alone and the company believes the study is highly unlikely to achieve success at the final analysis. Median overall survival was 10.1 months for patients treated with nemvaleukin in combination With pembrolizumab and 9.8 months for patients treated with investigator's choice chemotherapy (hazard ratio: 0.98). There has been a great deal of work across the industry in this immunologically cold tumor, yet there are still few treatment options that improve survival in this very difficult-to-treat tumor type. Nemvaleukin has a well characterized and favorable safety profile, both as a monotherapy and in combination with pembrolIZumab, with over 800 patients treated across the broader clinical program. Preliminary data readouts for less-frequent intravenous dosing of nemvaleukin in patients with cutaneous melanoma are expected in the second quarter of 2025 for cohort 3 of ARTISTRY-6 (monotherapy) and the second half of 2025 for cohort 4 of ARTISTRY-6 ("combination therapy), subject to patient enrollment. Annonce • Mar 12
Mural Oncology plc has filed a Follow-on Equity Offering in the amount of $75 million. Mural Oncology plc has filed a Follow-on Equity Offering in the amount of $75 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Transaction Features: At the Market Offering Annonce • Nov 13
Mural Oncology plc Provides Update on Pipeline Progress Mural Oncology plc's late-stage trials of nemvaleukin alfa (nemvaleukin), an engineered fusion protein designed to leverage Interleukin-2’s (IL-2) antitumor effects while mitigating its hallmark toxicities, remain on track. The company shared new information related to study design, statistical assumptions, and study execution at a virtual Investor Day in September 2024, including: Completion of enrollment in ARTISTRY-7, the company’s potentially registrational phase 3 trial in platinum-resistant ovarian cancer (PROC), with a total of 456 patients enrolled. The study is comparing the combination of nemvaleukin and pembrolizumab versus investigator’s choice single agent chemotherapy. Mural expects to report interim overall survival (OS) results in late FIRST QUARTER OF or early SECOND QUARTER OF based on an analysis performed at approximately 75% of OS events. If the hazard ratio meets the bar for success (0.727, or a 27.3% reduction in the risk of death assuming exactly 215 OS events), the company plans to file a Biologics License Application (BLA) in 2025 subject to discussions with the U.S. Food and Drug Administration (FDA). The company expects to report final results in the second quarter of 2026. · Completion of enrollment in ARTISTRY-6, Cohort 2, the company’s potentially registrational phase 2 study of single agent nemvaleukin in patients with unresectable or metastatic mucosal melanoma, with 92 patients enrolled. Mural anticipates reporting top-line results from cohort 2 of ARTISTRY-6 in SECOND QUARTER Of 2025. The target response rate is 25%. Mural believes that in this rare and highly aggressive tumor with poor outcomes even in the first line setting, demonstrating durable responses with a response rate of 20-25% would be meaningful for patients, and would support a discussion with the FDA regarding a BLA submission and potential accelerated approval. Mural is also evaluating a less-frequent intravenous (LFIV) dose of nemvaleukin in patients with cutaneous melanoma in ARTISTRY-6, Cohort 3 (monotherapy) and Cohort 4 (combination with pembrolizumab). The company continues to expect preliminary data readouts in the monotherapy cohort in the first half of 2025, and in the combination cohort in the second half of 2025. Mural plans to nominate development candidates for its IL-18 and IL-12 programs by the end of 2024. The company expects to submit an Investigational New Drug (IND) Application for its IL-18 program to the FDA in fourth quarter of 2025. Annonce • Nov 08
Mural Oncology Presents Clinical and Preclinical Data Across Its Pipeline At the 39Th Annual Meeting of the Society for Immunotherapy of Cancer Mural Oncology plc shared three poster presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer, taking place November 6-10, 2024 in Houston. Data presented from the ARTISTRY-3 clinical trial of Mural’s lead candidate, nemvaleukin alfa (nemvaleukin), showed tumor site-specific pharmacodynamic activity and immune activation in patients with ovarian cancer and mucosal melanoma. In addition, Mural presented preclinical data from its interleukin (IL)-12 and IL-18 programs that supported the company's unique protein engineering capabilities to overcome shortcomings associated with cytokines. Tumor microenvironment pharmacodynamic effect of nemvaleukin less frequent intravenous dosing in multiple solid tumors: results from the phase 1/2 ARTISTRY-3 study: Nemvaleukin is a novel, engineered fusion protein designed to leverage antitumor effects of the IL-2 pathway while mitigating the hallmark toxicities that have historically limited its use. ARTISTRY-3, a phase 1/2 study, evaluated less frequent intravenous dosing of nemvaleukin in advanced solid tumors. Paired biopsies were available from 8 patients across the three different dosing schedules of nemvaleukin. Collectively, LFIV nemvaleukin demonstrated tumor-site-specific pharmacodynamic activity and immune activation. Nemvaleukin treatment increased cytolytic NK and CD8 T cell densities in the tumor microenvironment. Density ratios of CD8 and NK cells relative to immune-suppressive Tregs were also favorable for the nemvaleukin LFIV regimen. The results were seen in biopsies from both mucosal melanoma and ovarian cancer tumors, supporting the hypothesis that nemvaleukin has the potential to recruit cytolytic effectors to poorly immunogenic tumor sites. Mural is currently running two late-stage, potentially registrational trials in platinum-resistant ovarian cancer (ARTISTRY-7) and mucosal melanoma (ARTISTRY-6, cohort 2), with data readouts expected in late Q1/early Second Quarter 2025 and Second Quarter 2025, respectively. Preclinical efficacy and immune activity of half-life extended IL-18 fusion proteins resistant to IL-18BP suppression. IL-18 is a potent immune-stimulating cytokine, but it is limited by IL-18 binding protein (IL-18BP), a secreted high-affinity decoy receptor that neutralizes IL-18, thus limiting its activity over time. Mural’s protein engineering aims to address the shortcomings of native IL-18 in two ways. First through the introduction of mutations designed to minimally impact the native structure while eliminating binding to IL-18BP. Secondly, by extending the half-life of IL-18BP via fusion to a protein scaffold to increase the cytokine’s exposure, allowing for sustained immune stimulation. In preclinical models, a weekly dosing regimen in mice provided durable immune responses and tumor growth inhibition. These mouse ortholog variants demonstrated resistance to IL-18BP and increased half-life, with durable expansion of immune-stimulating NK and CD8 T cells. These studies support pursuit of IND-enabling studies for first-in-human clinical trials. Mural plans to nominate a development candidate for its IL-18 program by the end of 2024 and intends to submit an Investigational New Drug (IND) Application to the FDA in Fourth Quarter 2025. Modulation of IL-12p70 exposure and activity following sequential administration of tumor targeted self-assembling split IL-12 subunits. IL-12p70 is a potent stimulator of the immune system with profound anti-tumor activity but very poor tolerability. Mural is developing an innovative approach to mitigate that toxicity by creating inactive split IL-12 subunits (IL-12p35 and IL-12p40) and assembling functional IL-12p70 predominantly in the tumor and tumor microenvironment. In murine models, increasing the interval time between subunit injections or reducing the dose level of the second subunit effectively modulated serum drug concentration while maintaining IL-12 levels in the tumor. Pharmacokinetics and pharmacodynamics were also assessed in non-human primates, where the inactive subunits were assembled and formed functional IL-12p70 in the periphery. Together, these data suggest Mural’s novel approach may unlock the potential of IL-12p70 as a therapeutic by mitigating the toxicity associated with systemic administration. Mural plans to nominate a development candidate for its IL-12 program by the end of 2024. Annonce • Sep 24
Mural Oncology plc Appoints Sachiyo Minegishi to its Board of Directors Mural Oncology plc announced the appointment of Sachiyo Minegishi to its board of directors, effective September 20, 2024. Ms. Minegishi will serve as Chair of the Audit Committee and will also be joining the company's Nominating and Corporate Governance Committee. With over 20 years of industry experience, Sachiyo brings a successful record of helping companies navigate through important clinical, financial, and corporate milestones. Sachiyo brings over two decades of biopharma experience, with a focus on corporate strategy, finance, development, and commercialization. She is currently the Chief Operating Officer at Rectify Pharmaceuticals, driving corporate and financing strategy to advance its lead program from discovery to clinical stage. Prior to Rectify, Sachiyo was Chief Financial Officer at Akouos Inc., where she led corporate finance and business development strategy and played a key role in the acquisition of the company by Eli Lilly. Before that, she was a Global Program Lead at bluebird bio, where she led a team to execute global development and commercialization strategy for a portfolio of gene therapies for sickle cell disease. Sachiyo has also held leadership roles that helped accelerate corporate growth at Human Genome Sciences, Genzyme, and Amgen. Annonce • Aug 01
Mural Oncology plc Announces the Appointment of George Golumbeski to its Board of Directors Mural Oncology plc announced the appointment of George Golumbeski, Ph.D., to its board of directors effective July 30. Dr. Golumbeski has extensive experience with strategic collaborations, M&A, in-licensing, out-licensing, and alliance management. He currently serves as a partner in DROIA Ventures, a specialist biotech investment firm focused on therapeutics for oncology and genetic disease. He previously served as President and Head of Corporate Development for GRAIL where he led corporate collaborations and served as an advisor to the CEO. Prior to GRAIL, Dr. Golumbeski was Executive Vice President of Business Development for Celgene (now a Bristol Myers Squibb company) where over his nine-year tenure he developed new models for corporate collaborations to drive corporate growth. He has also held leadership roles at Nabriva Therapeutics, Novartis Oncology, and Elan Biopharmaceuticals. Annonce • Jul 03
Mural Oncology plc(NasdaqGM:MURA) dropped from Russell 3000 Index Mural Oncology plc(NasdaqGM:MURA) dropped from Russell 3000 Index Annonce • Apr 14
Mural Oncology plc, Annual General Meeting, May 30, 2024 Mural Oncology plc, Annual General Meeting, May 30, 2024, at 13:00 Coordinated Universal Time. Location: Arthur Cox LLP at Ten Earlsfort Terrace, Dublin 2, D02 T380 Ireland Agenda: To elect, by separate resolutions, the five director nominees named in this proxy statement to the board of directors, to serve until the Company’s 2025 annual general meeting; to ratify, in a non-binding advisory vote, the selection of PricewaterhouseCoopers LLP as the Company’s independent auditor for the fiscal year ending December 31, 2024 and to authorize, in a binding vote, the board of directors, acting through the audit committee, to set the independent auditor’s remuneration; and to consider and act on such business as may properly come before the AGM or any adjournment or postponement thereof. Annonce • Jan 09
Mural Oncology plc Announces Enhancements to Late-Stage Clinical Trials Mural Oncology plc announced strategic changes to its ARTISTRY-6 and ARTISTRY-7 clinical trials designed to generate more meaningful clinical data for these late-stage, potentially registrational trials of nemvaleukin. These changes are as follows: Cohort 2 of ARTISTRY-6 is a potentially registrational, phase 2 trial evaluating nemvaleukin as a monotherapy in mucosal melanoma patients. Together have been thinking critically about the best ways to deliver treatments to patients who desperately need them. The company believe expanding patient enrollment in both potentially registrational trials, as well as shifting the primary endpoint of the ARISTRY-7 trial, may result in more meaningful clinical data. Now led by an experienced and highly accomplished oncology-focused executive team and board of directors, the company is leveraging its core competencies in immune cell modulation and protein engineering. Mural's lead product candidate, nemvaleukin, is being developed to treat a wide range of solid tumors. Mural is also advancing engineered therapies targeting interleukin-18 and interleukin-12, with plans to nominate development candidates for each program in 2024. The Company's cash resources of $275 million, as of November 15, 2023, are expected to fund its operations into fourth quarter 2025.